SCHEMBL2834650

SCHEMBL2834650

COc1cc(C)c(S(=O)(=O)NC2(COc3nccc(Cl)n3)CCC2)c(C)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADAM17 P78536 2/20 0.35
FFAR4 Q5NUL3 2/20 0.33
MEN1 O00255 4/20 0.33
KMT2A Q03164 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
LMNA P02545 2/20 0.33
TSHR P16473 2/20 0.33
HTT P42858 1/20 0.33
ALDH1A1 P00352 2/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 3/20 0.32
CCR9 P51686 1/20 0.32
NFE2L2 Q16236 2/20 0.31
TDP1 Q9NUW8 2/20 0.31
TP53 P04637 1/20 0.31
MAPT P10636 1/20 0.31
CXCR2 P25025 1/20 0.31
AGTR1 P30556 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
GRIN1 Q05586 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830925 0.79 HIF1A (0.41) SMN1; SMN2TSHRALDH1A1HPGD
SCHEMBL2836252 0.76 CCR9 (0.37) FFAR4MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL13232724 0.75 ALDH1A1 (0.40) FFAR4MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2333346 0.74 ALDH1A1 (0.39) FFAR4MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL2833909 0.70 BDKRB1 (0.43)
SCHEMBL2830420 0.69 CASP3 (0.40)
SCHEMBL2830422 0.69 CASP3 (0.40)
SCHEMBL2835290 0.69 BDKRB1 (0.37)
SCHEMBL2831492 0.69 PSEN1 (0.39)
SCHEMBL2834261 0.69 PSEN1 (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2356101-B1 PYRIMIDINE- AND TRIAZINE-SULFONAMIDE DERIVATIVES AS BRADYKININ B1 RECEPTOR (B1R) INHIBITORS FOR THE TREATMENT OF PAIN GRUENENTHAL GMBH (DE) 2013-02-27 EP disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-8269000-B2 Substituted pyrimidine and triazine compounds GRUENENTHAL GMBH (DE) 2012-09-18 US disclosed
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds GRUENENTHAL GMBH (DE) 2010-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173889-A1 Substituted Pyrimidine and Triazine Compounds ADORA2B, CCNB1, TYMS ADAM17 4776/4885FFAR4 2980/4885MEN1 4037/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.